Podcasts about prasad

Prasad Gollapalli is chief executive officer, founder and chairman of the board of Qued, a pioneering cloud-based AI workflow automation platform transforming load appointment scheduling into the future. It seamlessly automates the entire process, securing the optimal appointment times to all types of loads including multi-stop loads. By eliminating the chaos of spreadsheet management, overflowing inboxes, and cumbersome portal logins, Qued empowers 3PLs, brokers, and carriers with a streamlined workflow while delivering significant workforce optimization benefits for shippers. Through Qued, brokers build trust by guaranteeing on-time deliveries, enhancing communication, and fostering transparency, thereby strengthening industry relationships and enhancing efficiency and reliability. Qued's innovative approach has earned recognition from industry leaders such as McLeod Software, a premier freight management and transportation software provider, which has certified Qued as an integration partner. With nearly three decades of industry experience, Prasad is a seasoned entrepreneur renowned for his success in start-up ventures and leadership roles within trucking and shipping software companies. Prior to Qued, Prasad founded and led Trucker Tools, the industry's premier digital freight management platform with the most popular Trucker Tools driver app. As the CEO of Trucker Tools, he led the team in implementing innovative solutions including capacity management, predictive freight matching, automated booking, and real-time GPS-based visibility. Prasad sold Trucker Tools to ASG, a portfolio company of Alpine Investors, in June 2021. In December of 2024, DAT (a Roper Industries company) acquired Trucker Tools making ASG extremely happy with the outcome.  Prior to his tenure at Trucker Tools, Prasad held various leadership positions focused on the design and implementation of advanced transportation technology solutions. As Director of Product Management at Getloaded.com, later acquired by DAT, he led business and product strategy efforts. Prasad's expertise extends to the shipping industry, where he served as a product manager for the Liberian International Ship & Corporate Registry (LISCR, LLC). Prasad holds an MBA with a focus on strategy and entrepreneurship from the University of Maryland's Robert H. Smith School of Business, as well as a master's degree in Computer Science from the University of Alabama-Huntsville. He earned his bachelor's degree in computer science and engineering from the University of Madras, India. Prasad resides in Ashburn, Virginia, with his wife and daughter. Learn more about your ad choices. Visit megaphone.fm/adchoices

During Hour 1 we were joined by Nick Prasad from Bluejaysnation to recap the historic Blue Jays - Dodgers game 3. Hosted on Acast. See acast.com/privacy for more information.

Gheesu - Jayshankar Prasad - घीसू - जयशंकर प्रसाद - Suno Kahani #jayshankarprasad #jayshankarprasad #jayshankarprasadkikahani #jaishankarprasadkikahani #jaishankarprasadkikahaniyan #jaishankarprasadkikahani #hindikahaniyan #hindistories #kahani #kahaniyan #sunokahani #hindi #audiobook

“The line between AI workload and non-AI workload is getting blurrier by the day.” Prasad Kalyanaraman, VP of AWS Infrastructure Services, talks with Anurag Rana, Senior Technology Analyst at Bloomberg Intelligence, about what actually changes as AI scales. Prasad lays out the realities behind “AI data centers”: denser accelerators, non-blocking training networks, and modular in-chip liquid cooling. Underneath, the data-center basic priorities hold -— security as job zero, plus availability, performance, and cost. He also explains why clusters must be fungible between training and inference so accelerators and power never sit idle, and how AWS retrofits existing regions rather than treating AI as a separate build. 

In this special episode of 'Software People Stories,' , our guest is Dr. Krishna Prasad, known more popularly as KP from the 'Full Stack Leadership Cast.' KP shares his journey into podcasting, inspired by the host's longstanding podcast. They discuss the concept of full stack leadership, emphasizing a holistic approach to leadership that impacts business, influences people, and focuses on self-development. KP highlights his experiences from the first season, discussing the challenges of podcasting and the valuable insights gained from his diverse guests. They also delve into the prospects for the next season, including potential global guests and cross-industry learning.00:00 Introduction and Special Episode Announcement00:12 Welcoming the Guest: KP from Full Stack Leadership Cast01:29 KP's Podcasting Journey and Inspirations04:46 The Concept of Full Stack Leadership10:57 Insights from Season One15:47 Plans for Season Two and Listener Feedback21:05 Where to Listen and Final ThoughtsNote – above timings are approximate; exact timing may be off by a minute or soYou can listen to the Full Stack leadershipcast on YouTube https://www.youtube.com/playlist?list=PL4XtBUzCNYXDusMt0HS-T6-hl1BHXpyN9Or on the PM Power websitehttps://www.pm-powerconsulting.com/full-stack-leadershipcast/More on KP at: https://www.pm-powerconsulting.com/experts/krishna-prasad/

In today's episode, we explore one of Ayurveda's most fascinating diagnostic tools: the tongue. The art of tongue analysis, or Jivha Pariksha, allows practitioners to see what's happening in the body and mind before a single word is spoken, revealing the subtle imbalances, stagnation and vitality reflected on the surface of the tongue according to ancient texts.The Charaka and Sushruta Samhitas, the color coating, texture, and shape of the tongue, provide profound clues about an individual's health. In Ayurveda, the tongue is seen not merely as a muscle for taste and speech, but as a map linked to multiple organs and systems in the body. Key diagnostic insights include: detection of doshic imbalances, accumulation of toxins in the system, status of metabolic health, and signs of organ dysfunction.Joining us today is Dr. Rama Prasad. A distinguished Ayurvedic practitioner and educator with over three decades of clinical experience. Dr. Prasad is internationally recognized for his pioneering work in therapeutic fasting mind, body medicine, and holistic health assessment. He has been instrumental in introducing Ayurveda to Western health professionals through international conferences.Training programs and coaching. Currently, Dr. Rama leads innovative projects at Vaidyagrama Ayurveda Healing Village, where he focuses on online education, app development, and specialized wellness programs for a range of health conditions. His mission is to bridge the timeless principles of Ayurveda with modern healthcare, empowering both practitioners and clients to deepen their understanding of the body's innate intelligence.Today we dive into how the tongue serves as a mirror to the organs, what specific colors, textures, and shapes reveal about the doshas, and how Jivha Pariksha can help us detect and balance as long before they manifest as disease. So take a deep breath, settle in and prepare to see your health through a whole new lens: one that begins right at the tip of your tongue.Send us a textFor 20% off Kerala Ayurveda products, use code OjasOasis at checkoutFor 20% off GarryNSun products, use code OJASOASIS20 at checkout Support the showTo learn more about working with us, please visit www.OjasOasis.com Connect with us @ojasoasis on Instagram

Please visit Jasravee at ⁠⁠https://jasravee.com/⁠⁠Email Jasravee at jasravee@gmail.com

Coal India Limited or CIL — the world's largest coal mining company and one of India's most influential state-owned enterprises — is now 50 years old. Established to secure the India's energy needs, Coal India has long been the backbone of India's industrial and power sectors. But as the country moves toward its net-zero by 2070 goal, the company is now undergoing one of the most significant transformations in its history.From being the guardian of India's coal reserves, Coal India is venturing into new frontiers — investing in critical minerals, solar energy, and coal gasification — signalling a bold pivot toward a cleaner, more diversified energy future.In this episode of The India Energy Hour, we speak with P.M. Prasad, Chairman-cum-Managing Director of Coal India Limited, who reflects on his four-decade journey within the company and shares insights into its evolution, challenges, and vision for the future. Mr. Prasad discusses the founding mission of Coal India, its major milestones, and how the company plans to redefine itself in a decarbonising world.Full transcript of the episode is available in EnglishPresented by 101ReportersP.M. Prasad is on TwitterFollow TIEH podcast on Twitter, Linkedin & YouTubeOur hosts, Shreya Jai on Twitter, Linkedin & Dr. Sandeep Pai on Twitter, Linkedin

The profession of emergency management has been in flux since its inception.Currently the Trump Administration is looking how to organize the Federal EmergencyManagement Agency (FEMA) to fit with the President's political and policy agendas.Everything is perhaps up for grabs. In this podcast we look at one proposal to have theDepartment of Homeland Security (DHS) take over all aspects of what we might call“civil defense” to have those functions taken out of FEMA and aligned more directlywithin other elements of DHS.Michael Prasad is the executive director of the Center for Emergency ManagementIntelligence Research (www.cemir.org). CEMIR (www.cemir.org) has its own Substack,which can be subscribe to at https://thecemir.substack.com/ He leads researchprojects and writes professionally on emergency management policies andprocedures, from a pracademic perspective. Prasad holds a Bachelor of BusinessAdministration degree in management information systems from Ohio University, and aMaster of Arts degree in emergency and disaster management from American PublicUniversity.Please visit our sponsors!L3Harris Technologies' BeOn PPT App. Learn more about this amazing product here: www.l3harris.com Visit The Readiness Lab and learn about our Next Level Emergency Management training! https://www.thereadinesslab.com/Impulse: Bleeding Control Kits by professionals for professionals: www.dobermanemg.com/impulseDoberman Emergency Management Group provides subject matter experts in planning and training: www.dobermanemg.comCheck out how you can use digital twins in your training, exercising, and planning using RSET https://rset.com/ For sponsorship requests, check out our Sponsorship Portfolio here or email us at contact@thereadinesslab.comPlease visit our sponsors!L3Harris Technologies' BeOn PPT App. Learn more about this amazing product here: www.l3harris.com Visit The Readiness Lab and learn about our Next Level Emergency Management training! https://www.thereadinesslab.com/Impulse: Bleeding Control Kits by professionals for professionals: www.dobermanemg.com/impulseDoberman Emergency Management Group provides subject matter experts in planning and training: www.dobermanemg.comCheck out how you can use digital twins in your training, exercising, and planning using RSET https://rset.com/ For sponsorship requests, check out our Sponsorship Portfolio here or email us at contact@thereadinesslab.com

In this episode, film editor Pranav Sri Prasad joins Ebin Philip to dive deep into the world of cinematic storytelling through editing. From working on Bhageera to collaborating with directors who truly understand the rhythm of a scene, Pranav shares his creative process, tools, and the art of finding emotion in every cut.If you're passionate about filmmaking, storytelling, or simply curious about what goes on inside an editor's mind — this conversation is for you.

In this episode, film editor Pranav Sri Prasad joins Ebin Philip to dive deep into the world of cinematic storytelling through editing. From working on Bhagira to collaborating with directors who truly understand the rhythm of a scene, Pranav shares his creative process, tools, and the art of finding emotion in every cut.If you're passionate about filmmaking, storytelling, or simply curious about what goes on inside an editor's mind — this conversation is for you.

In this episode of The Pastoral Thoughts Podcast, Pastor Jack Young sits down with Vara Prasad, a missionary to India whose life and ministry reflect remarkable courage and faith. Born into a pastor's home, Vara grew up watching his father plant churches and preach the gospel amid growing persecution. Though trained as a computer programmer, Vara eventually surrendered to God's call to preach after a life-changing illness. Today, he ministers in a nation where sharing the gospel can cost you your freedom—or your life.Hear Vara's firsthand account of imprisonment, harassment by authorities, and the boldness of believers who continue to worship despite opposition. His story is a powerful reminder that the gospel still advances—even under fire.

Dancing Elephant was founded by Saira Malhotra, an internationally trained chef and TV personality, and Chandni Prasad, an Ayurvedic wellness advocate with deep roots in public service and global policy.Rooted in tradition but reimagined for today, Dancing Elephant brings this beloved Indian staple to the American market with a fresh, vibrant perspective. what we chat about:The roots of kitchari + why it's such comforting meal in South Asian homesHow Dancing Elephant reimagined kitchari for today's busy, wellness-conscious eaters without losing its soulSaira & Chandni's third-culture experienceIG dancingelephant_ayurveda | thedancingelephant.comFind Me:IG + TikTok citrusdiaries.studiocitrusdiaries.com | hello@citrusdiaries.comCreate your ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ today! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#madeonzencastr

Join Craig Fuller and freight tech veteran Prasad Gollapalli (Founder of Trucker Tools and Queued) as they dive deep into the brutal competition and market dynamics shaking up the load board ecosystem. #FreightTech #LoadBoards #Trucking #DAT #Highway #TruckStop #Logistics #SupplyChain #FreightRecession #Entrepreneurship Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Craig Fuller and freight tech veteran Prasad Gollapalli (Founder of Trucker Tools and Queued) as they dive deep into the brutal competition and market dynamics shaking up the load board ecosystem. #FreightTech #LoadBoards #Trucking #DAT #Highway #TruckStop #Logistics #SupplyChain #FreightRecession #Entrepreneurship Learn more about your ad choices. Visit megaphone.fm/adchoices

Chef Prasad Chirnomula is an award-winning chef and a two time Honoree of the popular James Beard Foundation. Chef Prasad owns and operates Chef Prasad in New Canaan, CT and Gourmet United in Easton, CT.Episode Sponsors:The Amber Room Colonnade⁠⁠⁠⁠⁠https://www.theamberroom.net/⁠⁠⁠⁠⁠Affinity Esports⁠⁠⁠⁠https://www.affinityesports.gg/⁠⁠⁠⁠Negative Kitty⁠⁠⁠⁠https://linktr.ee/negative_kitty⁠

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Senior Editor Sue Sutter discuss the impact of US Food and Drug Administration's COVID-19 vaccine indication changes and recission of the associated emergency use authorizations, as well as the postmarketing studies that now are required (:40), and their potential impact on access and reimbursement (12:20). More On These Topics From The Pink Sheet COVID-19 Vaccines: Pfizer Arguments To Keep EUA Failed To Persuade US FDA's Prasad: https://insights.citeline.com/pink-sheet/vaccines/covid-19-vaccines-pfizer-arguments-to-keep-eua-failed-to-persuade-us-fdas-prasad-V3X2OEBZE5HRHKO7KMMCFXBM2Q/ US FDA Updates COVID-19 Vaccine Formulations, Revokes EUAs, ACIP Use Decision Next: https://insights.citeline.com/pink-sheet/vaccines/us-fda-updates-covid-19-vaccine-formulations-revokes-euas-acip-use-decision-next-VBXJDSOA6BCOXNCA2TAH27EBJY/ A US FDA Move to Revoke Pfizer's Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions: https://insights.citeline.com/pink-sheet/vaccines/a-us-fda-move-to-revoke-pfizers-pediatric-covid-19-vaccine-eua-could-raise-supply-questions-ZX26DBENHFCOHPBGMPFPQB6REQ/ Changes In Pediatric COVID-19 Vaccine Recommendations Causing Coverage Confusion: https://insights.citeline.com/pink-sheet/vaccines/changes-in-pediatric-covid-19-vaccine-recommendations-causing-coverage-confusion-WDEYUVJXGBCGBEVBQ2I6INH554/

TOPIC: Car Tech PANEL: Dr. Prasad, CAR; Paul Eisenstein, Headlight.news; Gary Vasilash, shinymetalboxes.net; John McElroy, Autoline.tv

Colette is joined by Ayurvedic doctor and educator Vaidya Princy Prasad for a deeper exploration of Agni, the inner fire that fuels far more than just digestion. While Agni is often associated with metabolism, its influence extends into immunity, hormonal balance, emotional clarity, and overall vitality. In this conversation, they discuss the following: What Agni really is and why it's central to vibrant health and ojas The different types of Agni and various levels of action Signs of optimal (sama) Agni and what happens when it's imbalanced The types of impaired Agni: Vishama, Tikshna and Manda How Agni influences key hormones  Practical Ayurvedic tips to kindle and sustain a balanced Agni Why seasonal cleansing is vital for reseting Agni * Thanks to Kerala Ayurveda Academy for sponsoring this episode. Explore upcoming trainings at Kerala Ayurveda Academy. Use code ELEMENTS100 to save $100 on your enrollment. Learn more at keralaayurveda.us/courses. * Click here to register for the discounted Digestive Reset Cleanse starting October 3rd, 2025 * Visit Colette's website www.elementshealingandwellbeing.com  Online consultations & Gift Vouchers Next discounted Group Cleanse starts October 3rd, 2025 Private at-home Digestive Reset Cleanse tailored to you Educational programs - Daily Habits for Holistic Health Reset-Restore-Renew Program Have questions before you book? Book a FREE 15 min online Services Enquiry Call * Join the Elements of Ayurveda Community! * Stay connected on the Elements Instagram and Facebook pages. * Enjoy discounts on your favourite Ayurvedic products: Banyan Botanicals - enter discount code EOA15 at checkout for 15% off your first purchase.** Divya's  - enter discount code ELEMENTSOFAYURVEDA15 at checkout for 15% off your first purchase.** Kerala Ayurveda - enter discount code ELEMENTS15 to receive 15% off your first purchase.** LifeSpa - Save $10 on a $50 or more one-time purchase with the code elements10.  **Shipping available within the U.S. only. * Thank you for listening! If this episode supported you, please consider leaving a review and if you think this information would be helpful to family or friends, please share this episode so we can spread this wisdom of Ayurveda.  Stay tuned and stay aligned with the Elements of Ayurveda Podcast.      

Resorbable embolics are gaining traction in musculoskeletal interventions, but what are the key technical considerations? Dr. Keerthi Prasad, interventional radiologist at the Centers for Pain Control and Vein Care joins host Dr. Ally Baheti to share practical insights when using resorbable embolics in MSK interventions.---This podcast is supported by:OBL Marketinghttps://www.oblmarketing.com---SYNPOSISDr. Prasad opens the conversation with an overview of embolic agents used in MSK interventions—including Imipenem, Lipiodol, and Nexsphere-F—and shares practical insights into technique selection. He explores the nuances of working with various resorbable embolics, highlighting clinical cases from his personal experience. The discussion also highlights Dr. Prasad's innovative approach to establishing an outpatient-based lab (OBL) focused on musculoskeletal interventions. Additionally, Dr. Prasad also offers insight into the expanding role of resorbable embolics in treating conditions such as knee arthritis, plantar fasciitis, and adhesive capsulitis. The episode ends with a call to broaden access to this evolving treatment.---TIMESTAMPS00:00 - Introduction01:55 - Outpatient Embolization and MSK Procedures04:20 - Resorbable Embolics in Joint Embolization04:52 - Available Resorbable Embolics in the US07:57 - Technical Insights on Using Resorbable Embolics15:18 - Patient Outcomes and Long-Term Durability22:24 - Future of MSK Embolization Techniques24:05 - Exploring New Applications for Resorbable Embolics27:30 - Innovative Procedures and Techniques37:00 - Final Thoughts and Advice for Practitioners

Resorbable embolics are gaining traction in musculoskeletal interventions, but what are the key technical considerations? Dr. Keerthi Prasad, interventional radiologist at the Centers for Pain Control and Vein Care joins host Dr. Ally Baheti to share practical insights when using resorbable embolics in MSK interventions.---This podcast is supported by:Medtronic OsteoCoolhttps://www.medtronic.com/en-us/healthcare-professionals/products/surgical-energy/ablation/radiofrequency-ablation/systems/osteocool-2-0-bone-tumor-ablation-system.html---SYNPOSISDr. Prasad opens the conversation with an overview of embolic agents used in MSK interventions—including Imipenem, Lipiodol, and Nexsphere-F—and shares practical insights into technique selection. He explores the nuances of working with various resorbable embolics, highlighting clinical cases from his personal experience. The discussion also highlights Dr. Prasad's innovative approach to establishing an outpatient-based lab (OBL) focused on musculoskeletal interventions. Additionally, Dr. Prasad also offers insight into the expanding role of resorbable embolics in treating conditions such as knee arthritis, plantar fasciitis, and adhesive capsulitis. The episode ends with a call to broaden access to this evolving treatment.---TIMESTAMPS00:00 - Introduction01:55 - Outpatient Embolization and MSK Procedures04:20 - Resorbable Embolics in Joint Embolization04:52 - Available Resorbable Embolics in the US07:57 - Technical Insights on Using Resorbable Embolics15:18 - Patient Outcomes and Long-Term Durability22:24 - Future of MSK Embolization Techniques24:05 - Exploring New Applications for Resorbable Embolics27:30 - Innovative Procedures and Techniques37:00 - Final Thoughts and Advice for Practitioners

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses Vijay Prasad's return to the FDA, revoking of COVID vaccine authorization for young children, the Legionnaires' outbreak in Harlem, the new labeling requirements for Ixchiq, the infectious attenuated Chikungunya vaccine and the importation of H5 influenza virus in Antarctica, before Dr. Griffin deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, guidelines for treating COVID-19, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, the association of “virus rebound” and post-acute sequelae among hospitalized patients, how virus infection particularly influenza and SARS-CoV-2 may ‘re-activate' dormant cancer cells and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Prasad returns to the FDA (Washington Post) Pfizer Covid vaccine for young children may not be renewed by FDA (The Guardian) Report suggests FDA may not reauthorize Pfizer COVID vaccine for young kids (CIDRAP) Factors Associated With Pediatric COVID-19 Mortality: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study (Journal of Pediatric Infectious Diseases Society) Legionnaires' Disease: In Harlem (NYC Health) Recommended Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated (FDA) FDA Removes Recommended Pause in Use and Approves Required Updated Labeling (FDA) Chikungunya Vaccines (CDC: Chikungunya virus) Chikungunya in China (CDC: Travelers' Health) Travelers' health notices (CDC: Travelers' Health) Areas at Risk for Chikungunya (CDC: Chikungunya virus) Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years (CID) Tracking HPAIV H5 through a geographic survey of Antarctic seabird populations (Scientific Reports) Report details first suspected H5 avian flu detections in seabirds in Antarctica(CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) ENFLONSIA: novel drug approvals 2025 (FDA) RSV-Network (CDC Respiratory Syncytial virus Infection) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness (CID) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Paxlovid (Pfizer) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID TWiV 1243: Capitalism, COVID and Cancer (MicrobeTV) Respiratory viral infections awaken metastatic breast cancer cells in lungs(Nature) Reaching out to US house representative Letters read on TWiV 1244 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

TODAY ON THE ROBERT SCOTT BELL SHOW: FDA's Dr. Prasad Returns, Gut Health Illness Connection, The Boomer Mirage, ChatGPT Bad Health Advice, Lachnanthes Tinctoria, FDA to end EUA, Laurie Hammer, Calm Mom Method, Comment of the Day, Medicaid Vax Rush and MORE! https://robertscottbell.com/fdas-dr-prasad-returns-gut-health-illness-connection-the-boomer-mirage-chatgpt-bad-health-advice-lachnanthes-tinctoria-fda-to-end-eua-laurie-hammer-calm-mom-method-comment-of-the-day-medic/ https://boxcast.tv/view/fdas-dr-prasad-returns-gut-health-illness-connection-the-boomer-mirage-laurie-hammer-calm-mom-method---the-rsb-show-8-13-25-b5frzcmphayesomqybg2 Please read this disclaimer carefully before you (“you”, “your”) use our [Your Website URL] website (“website”, “service”) operated by the [Your Business Name] (“operator”, “us”, “we”, “our”). Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Vinay Prasad is back at the FDA as chief of the FDA's Center for Biologics Evaluation and Research. Prasad's return—which hit the news wires Saturday morning—came just 10 days after his unexpected exit on July 29, following blowback over the saga involving Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy Elevidys, and a campaign by conversative personalities to oust the outspoken physician.Elsewhere in the government, Gray Delany, former head of HHS' and President Donald Trump's Make America Healthy Again agenda, has been fired—days after Health and Human Services Secretary Robert F. Kennedy Jr. axed 22 mRNA vaccine contracts under the Biomedical Advanced Research and Development Authority. Delany's ouster came after he allegedly butted heads with other agency officials over how announcements were made, according to reporting from Endpoints News. The mRNA contract cuts, meanwhile, have sparked criticism from the scientific community and concern that the growing anti-mRNA sentiment could also have a negative effect on research for cancer therapeutics.In somewhat related news, the Annals of Internal Medicine is refusing to retract a large-scale study it ran in July that pointed to the lack of an association between childhood aluminum exposure through vaccination and chronic conditions, despite Kennedy's criticism. In an op-ed published earlier this month, the Health Secretary took issue with the study's design.In obesity news, biopharma darling Eli Lilly suffered a rare chink in its normally impenetrable GLP-1 armor. The first Phase III trial for oral weight loss therapy orforglipron read out last week, and the results were underwhelming, at least to Wall Street. Truist Securities wrote that the data support approval but “leaves room for competition.” This is good news for a whole host of companies, including Roche, Viking, Terns and Rhythm Pharmaceuticals, who all have weight loss pills at various stages of development.And in gene therapy, the hits just keep coming. The FDA has limited the use of bluebird bio's gene therapy Skysona to patients with cerebral adrenoleukodystrophy for whom no other therapies or stem cell donors are available, due to a heightened risk of blood cancers. This follows safety issues in gene therapy trials experienced by Allogene, and, of course, Sarepta Therapeutics. This week in ClinicaSpace, Dan Samorodnitsky explored the future of AAV technology. And in BioPharm Executive, Annalee Armstrong sat down with Chris Anzalone, CEO of Arrowhead Pharmaceuticals—Sarepta's key strategic partner—to learn how his company has been weathering the storm.

Phase III data from Lilly's orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and wide use. On the latest BioCentury This Week podcast, BioCentury's analysts discuss why the first-in-class oral small molecule GLP-1R agonist's clean safety profile and clear manufacturing advantage over oral peptides give the product a leg-up in the market.They then discuss Vinay Prasad's return to FDA after a brief hiatus, the revamped strategy of 32-year-old San Diego biotech Acadia Pharmaceuticals, and an attempt in the Senate to revive the Biosecure Act targeting China biotechs.Finally, the analysts preview this year's Back to School package, which reimagines FDA. At a time of unprecedented change in government agencies, BioCentury's 33rd Back to School asks what FDA could look like if it were reorganized from the ground up to create the regulator patients deserve and industry needs. View full story: https://www.biocentury.com/article/656727#orforglipron #CBER #VinayPrasad #AcadiaPharmaceuticals00:00 - Introduction00:49 - Prasad07:09 - Back to School12:29 - Lilly Obesity21:58 - Acadia's Comeback28:50 - Biosecure ActTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vinay Prasad has returned to the FDA as the Chief of the Center for Biologics Evaluation and Research, just 10 days after his mysterious departure. His return comes after a short "vacation" in California, and it is believed that the regulator convinced him to come back. Some speculate that Prasad's time away may have helped him gain a better understanding of the complexities involved in decision-making at the FDA, especially when it comes to ensuring the safety of patients and meeting the needs of various stakeholders. This unexpected turn of events has generated interest and optimism among industry insiders.Gilead remains positive about the prospects of its HIV prevention drug, despite uncertainties surrounding recommendations from the U.S. Preventive Services Task Force. The FDA has launched a new program to help pharmaceutical companies lower regulatory barriers to manufacturing in the U.S. Other news includes Dewpoint Therapeutics slashing headcount, Novartis rumored to be taking over RNA specialist Avidity, and Trilink Biotechnologies offering process development services for nucleic acid therapeutic development. Lotte Biologics is expanding its global manufacturing bases, while other companies like Bicycle, Tune, and Iovance are downsizing to conserve cash. The FDA is in flux, Pfizer is discussing pricing with Trump, and Merck is cutting jobs. Vertex's next-generation pain drug failed in trials despite strong Q2 earnings. Thank you for listening to Pharma and Biotech daily: your source for quick updates on the latest news in the pharmaceutical and biotechnology industries.

On this week's episode, Eric Schmidt, Paul Matteis, Sam Fazeli, and Brian Skorney begin with a recap of the week's Sarepta news, covering their initial refusal then agreement to pause Elevidys shipments, if it can return to the market, the broader lessons for the biotech industry, and the communication breakdown between Sarepta and the FDA. Continuing with regulatory news, the group discusses the appointment of George Tidmarsh as the new CDER director and his role within FDA leadership. The conversation then turns to Replimune's CRL for RP1 melanoma, Prasad's likely influence in the rejection, and the impact on the investment community. In data news, the group overviews Alkermes' positive Phase 1 data for its orexin 2 receptor agonist for type 1 narcolepsy, along with the safety controversy, and Abivax's Phase 3 ulcerative colitis data and stock spike. Prime Medicine's decision to reprice shares and strategies for better talent retention is also highlighted. The episode concludes with a brief overview of first-half 2025 licensing data, Roche earnings, and AstraZeneca's $50 billion U.S. investment. *This episode aired on July 25, 2025.

In this episode, Prasad Baji, Mumbai Chapter Chair and Board Member of Social Venture Partners India, reflects on the growing trend of professionals entering the philanthropic space in India. Drawing from his own transition from corporate investment banking to the social sector, he shares thoughtful insights on why professionals bringing their lived experience, values, and skills into philanthropy signals a promising shift for the sector.

Dive deep into Nepal's rich history and culture with renowned historian and professor Mohan Prasad Khanal in this comprehensive podcast. Explore Nepal's ancient civilizations, from prehistoric times to the early societal structures that shaped the nation. Learn about Nepal's unique non-rectangular flag, a timeless symbol of its identity, and discover the fascinating early currency systems including Pan, Puraan, and Kaashapan. Gain insight into Nepal's vibrant festivals and the historical caste system, including the history of the Sudhra caste and the origins of Aaadi Wasi. The podcast also sheds light on women's rights and gender roles in ancient Nepal, highlighting respect towards women 1400-1500 years ago. Experience the thrilling historic showdown involving King Maandev's army, elephants, and new weapons, as well as Nepal's significant trade routes and commerce in early history. Professor Khanal also addresses misconceptions in Indian historiography and shares his final thoughts on Nepal's civilizational journey. Whether you're interested in Nepal's social evolution, military history, or cultural heritage, this podcast offers a detailed and engaging narrative. Subscribe and join us to uncover the untold stories of Nepal's past and its enduring legacy. Keywords: Nepal history, ancient civilizations, historian Mohan Prasad Khanal, caste system, early currency, festivals, women's rights, historic showdown, trade routes, Nepal culture.

The ouster of Vinay Prasad after three months running FDA's Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On the latest BioCentury This Week podcast, BioCentury's analysts discuss what the latest shakeup at the regulatory agency says about what's next for FDA.The analysts also assess two leading European pharmas: obesity and diabetes company Novo Nordisk, which named a new CEO last week while cutting its 2025 forecast, and Bayer, which is gearing up for launches and is revamping its pipeline to restart growth. Finally, they discuss the promising clinical data that's reviving interest in masking technologies that conditionally activate biologics.View full story: https://www.biocentury.com/article/656649#FDA #CBER #NovoNordisk #ObesityDrugs #Bayer01:05 - Prasad's Ouster14:59 - Novo's New CEO21:14 - Bayer's Growth Strategy26:05 - Masked BiologicsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 1, 2025. In this episode: EU tariff deal leaves questions for pharma; Prasad's CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AOJAANRHLNCPNNLNGVVKA3HEAE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

In this episode, we break down the high-profile firing of Dr. Vinay Prasad from his FDA leadership post. Once hailed as a contrarian voice in medicine, Prasad quickly became a polarizing figure both inside and outside the agency. We explore the tangled web of political infighting, pressure from Big Pharma, the biotech industry, and conspiracy theorists like Laura Loomer—and why this decision may have less to do with science and more with chaos at the top. Connect with us further on https://sciencebasedmedicine.org/author/jonathanhoward/  The Fine Print The content presented in the "We Want Them Infected" Podcast and associated book is intended for informational and educational purposes only.    The views and opinions expressed by the speakers, hosts, and guests on the podcast do not necessarily reflect the views of the creators, producers, or distributors. The information provided in this podcast should not be considered as a substitute for professional medical, scientific, or legal advice. Listeners and readers are encouraged to consult with relevant experts and authorities for specific guidance and information.   The creators of the podcast and book have made reasonable efforts to ensure that the information provided is accurate and up to date. However, as the field of medical science and the understanding of the COVID-19 pandemic continue to evolve, there may be new developments and insights that are not covered in this content.   The creators are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. They disclaim any liability for any loss, injury, or damage incurred by individuals who rely on the content.   Listeners and readers are urged to use their judgment and conduct their own research when interpreting the information presented in the "We Want Them Infected" podcast and book. It is essential to stay informed about the latest updates, guidelines, and recommendations related to COVID-19 and vaccination from reputable sources, such as government health agencies and medical professionals. By accessing and using the content, you acknowledge and accept the terms of this disclaimer.   Please consult with appropriate experts and authorities for specific guidance on matters related to health, science, and the COVID-19 pandemic.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Moderna CEO Stephane Bancel has stated that the company is not interested in pursuing mergers and acquisitions, preferring to focus on research and development partnerships instead. Former President Trump has threatened 17 big pharmaceutical companies with a deadline to lower drug prices or face government intervention. Regeneron faces regulatory issues affecting decision dates for high-dose Eylea, while Moderna has won a UK patent battle against Pfizer and BioNTech. After the removal of FDA chief Dr. Prasad, Dr. Makary is seeking better alignment between drug and biologic approvals at the agency. Alnylam's impressive sales of Amvuttra ATTR-CM have led to a surge in stock prices, while Merck is aiming to save $3 billion through job cuts. Moderna is also cutting 10% of its global workforce. Recent FDA approvals for myeloma and Alzheimer's treatments, as well as updates on layoffs and pipeline developments in the biotech industry are also making headlines.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners.This episode covers South Asian mental health with Dr. Farooq Naeem, a senior scientist with the Institute for Mental Health Policy Research and a psychiatrist at the Centre for Addiction and Mental Health. He is also a professor of psychiatry at the University of Toronto.Dr. Naeem pioneered techniques for culturally adapting CBT. These techniques have been used to adapt CBT in South Asia, North Africa, Middle East, Kenya and China. His research areas include CBT, psychosis, and culture, with an overall aim to improve access to CBT. He has also published on issues related to health services and quality improvement. He works with a team of IT experts and has developed a CBT-based therapy program — called eGuru — that can be delivered through web and smartphone apps.The learning objectives for this episode are as follows:By the end of this episode, you should be able to…Recognize the unique mental health challenges and barriers faced by South Asian communitiesUnderstand how cultural nuances shape mental health presentations and assessmentsDescribe culturally adapted CBT and its benefits for South Asian patientsIdentify initiatives and future directions in transcultural psychiatry for South AsiansGuest: Dr. Farooq NaeemHosts: Hira Ahmad, Gurvir Rai, Nikhita SinghalAudio editing by: Nikhita SinghalShow notes by: Nikhita SinghalResources:PsychEd Episode 29: Cultural Psychiatry with Dr. Eric JarvisCulturally Adapted Cognitive Behavioural Therapy for Canadians of South Asian OriginSouth Asian Canadian Mental Health FoundationSociety for the Study of Psychiatry and CultureReferences:Gadalla, T.M. (2010). Ethnicity and seeking treatment for depression: a Canadian national study. Canadian Ethnic Studies 41(3), 233-245. https://doi.org/10.1353/ces.2010.0042Karasz, A., Gany, F., Escobar, J., Flores, C., Prasad, L., Inman, A., Kalasapudi, V., Kosi, R., Murthy, M., Leng, J., & Diwan, S. (2019). Mental health and stress among South Asians. Journal of Immigrant and Minority Health, 21(S1), 7–14. https://doi.org/10.1007/s10903-018-0790-4Kumar, A., & Nevid, J. S. (2010). Acculturation, enculturation, and perceptions of mental disorders in Asian Indian immigrants. Cultural Diversity and Ethnic Minority Psychology, 16(2), 274–283. https://doi.org/10.1037/a0018352Lai, D. W. L., & Surood, S. (2008). Socio-cultural variations in depressive symptoms of ageing South Asian Canadians. Asian Journal of Gerontology and Geriatrics, 3(2), 84-91.Leung, P., Cheung, M., & Tsui, V. (2011). Asian Indians and depressive symptoms: Reframing mental health help -seeking behavior. International Social Work, 55(1), 53–70. https://doi.org/10.1177/0020872810372801Masood, N., Okazaki, S., & Takeuchi, D. T. (2009). Gender, family, and community correlates of mental health in South Asian Americans. Cultural Diversity and Ethnic Minority Psychology, 15(3), 265–274. https://doi.org/10.1037/a0014301Vakil, K., Desse, T. A., Manias, E., Alzubaidi, H., Rasmussen, B., Holton, S., & McNamara, K. P. (2023). Patient-centered care experiences of first-generation, South Asian migrants with chronic diseases living in high-income, Western countries: systematic review. Patient Preference and Adherence, 17, 281–298. https://doi.org/10.2147/PPA.S391340For more PsychEd, follow us on Instagram (@psyched.podcast), Facebook (PsychEd Podcast), X (@psychedpodcast), and Bluesky (@psychedpodcast.bsky.social‬). You can email us at psychedpodcast@gmail.com and visit our website at psychedpodcast.org.

Urvashi Prasad has spent the last 15 years trying to make the world a kinder, fairer, and better place through her policy-based interventions in heathcare. Armed with degrees from Cambridge and LSTH, she worked as a director at NITI Aayog, and was awarded the India-UK Achievers Award. In addition to sharing principles and frameworks for building meaningful careers in public policy, Urvashi opens up about losing her beloved father and being diagnosed with cancer soon after. We admire her resilience and are proud to share her story with you. Here you will learnHow governments attempt to address systemic challenges in sectors like healthcareHow young professionals can carve out interesting and impactful careers in public policy How to make sense of life when you lose your beloved parent and are diagnosed with cancerUrvashi Prasad is a public health and policy advisor with over 15 years of leadership across government, academia, and grassroots innovation. As Director in the Office of the Vice Chairperson at NITI Aayog, India's apex policy think tank, she helped shape the country's COVID-19 response strategy, monitor Sustainable Development Goals in real time, and spearhead national programs advancing public health, gender equity, and social inclusion.A co-author of India's first Voluntary National Review presented at the UN High-Level Political Forum in 2017, Urvashi's policy insights have been featured in 150+ publications globally. She is also the British Council's UK Alumni Ambassador for SDG 10, an Honorary Professor at De Montfort University, UK, and a member of the World Economic Forum's Expert Network. Her accolades include the India-UK Achievers Honors and recognition among India's most influential women. In 2023, she founded Spcace by Urvashi, a pioneering platform amplifying patient voices.Diagnosed with Stage 4 ALK-positive lung cancer at age 35, Urvashi now brings lived experience to the policy table --challenging invisibility in cancer discourse and driving recognition of under-researched malignancies in young adults. Her advocacy bridges science, storytelling, and systemic reform.She holds a master's in public health from the London School of Hygiene & Tropical Medicine, an MPhil in Bioscience Enterprise from Cambridge University, and a Bachelor's in Biological Sciences (Genetics) from the University of Birmingham, UK. In 2024, Urvashi received an honorary doctorate for her work in public health and policy.

The FDA is unraveling. Scientists are being fired, vaccine access is shrinking, and top researchers are fleeing the country. And at the center of the storm? RFK Jr.'s appointees—Marty Makary and Vinay Prasad—men who once sat behind keyboards criticizing pandemic policy, now wield real power with devastating results. In this week's episode, Jonathan and Wendy walk us through the chaos: from dismissals without explanation to fabricated claims about who's being laid off, to the surreal moment when the very people who told us COVID was like the flu are now deciding who gets vaccinated. They call out journalist John Tierney for whitewashing pandemic history and expose the hypocrisy of pundits who cheered on herd immunity while vilifying actual public health officials. This isn't just a takedown—it's a warning. When contrarians become the establishment, science doesn't just get silenced. It gets rewritten. The FDA is unraveling. Scientists are being fired, vaccine access is shrinking, and top researchers are fleeing the country. And at the center of the storm? RFK Jr.'s appointees—Marty Makary and Vinay Prasad—men who once sat behind keyboards criticizing pandemic policy, now wield real power with devastating results. In this week's episode, Jonathan and Wendy walk us through the chaos: from dismissals without explanation to fabricated claims about who's being laid off, to the surreal moment when the very people who told us COVID was like the flu are now deciding who gets vaccinated. They call out journalist John Tierney for whitewashing pandemic history and expose the hypocrisy of pundits who cheered on herd immunity while vilifying actual public health officials. This isn't just a takedown—it's a warning. When contrarians become the establishment, science doesn't just get silenced. It gets rewritten.   Connect with us further on https://sciencebasedmedicine.org/author/jonathanhoward/  The Fine Print The content presented in the "We Want Them Infected" Podcast and associated book is intended for informational and educational purposes only.    The views and opinions expressed by the speakers, hosts, and guests on the podcast do not necessarily reflect the views of the creators, producers, or distributors. The information provided in this podcast should not be considered as a substitute for professional medical, scientific, or legal advice. Listeners and readers are encouraged to consult with relevant experts and authorities for specific guidance and information.   The creators of the podcast and book have made reasonable efforts to ensure that the information provided is accurate and up to date. However, as the field of medical science and the understanding of the COVID-19 pandemic continue to evolve, there may be new developments and insights that are not covered in this content.   The creators are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. They disclaim any liability for any loss, injury, or damage incurred by individuals who rely on the content.   Listeners and readers are urged to use their judgment and conduct their own research when interpreting the information presented in the "We Want Them Infected" podcast and book. It is essential to stay informed about the latest updates, guidelines, and recommendations related to COVID-19 and vaccination from reputable sources, such as government health agencies and medical professionals. By accessing and using the content, you acknowledge and accept the terms of this disclaimer.   Please consult with appropriate experts and authorities for specific guidance on matters related to health, science, and the COVID-19 pandemic.  

A Unique listening experience. Book / Manushya Janma / Written by Devi Prasad Chattopadhyay / Translated by Nishanath Manna/Sound Designing and Audio Mastering by Dr GuriMadhu Bhandari00:03Rubi Snita01:20Shraddha Singh04:44Dr Guri06:35Vibha Mahajan11:02Shubham Mishra12:47Bushra Fatma15:21Jyoti Nanda18:11Kashan Mustafa20:26Irfan24:40Poonam Ahmad26:01Shrey Harbhajanka26:51Kumar Nishant28:14Aditya Agnihotri30:46Naresh Kaushik32:40Mukesh Burnwal35:21Pragati Pandey37:03Satyarth Anirudh 39:30Sanjay Kumar41:13Shalini Singh42:59Suman Shekar45:06Aditya Ranjan48:59Vardan Dixit51:00Poonam Ahmad53:12Dr Guri54:01Listen with Irfan (LwI)A tapestry of voices and stories, spun with careSupport LwI — a soulful creation shaped by affection, thriving on the warmth of its listeners. Your contribution helps keep this free, bringing global stories, rare sound recordings, and personal music archives to all without paywalls. I curate voices, readings from literature, and cultural studies with immense care.Through my recent initiative, Read Aloud Collective, voices from around the world are coming together in celebration of spoken word.Grateful for your love -keep listening, keep supporting!  Curator: IrfanSupport LwI by contributing:  https://rzp.io/rzp/MemorywalaYour comments and feedback are welcome. Write to ramrotiaaloo@gmail.comCurated and Cover Designed by: Irfan

Today we discuss sex and vaccines, reality and renegades. First: men can no longer compete in women's sports—from Trump's Executive Order, to the NCAA's response, to William “Lia” Thomas having his records rescinded at Penn, reality is prevailing. Other evidence includes the UK Supreme Court declaring that “man” and “woman” refer to biological reality; and the U.S. Supreme Court writing an opinion that forcing LGBTQ+ books on children in public elementary schools is unconstitutional. Men cannot magically turn into women, nor boys into girls, no matter what they believe or are told. Then: from the ACIP (Advisory Committee on Immunization Practices) to Vinay Prasad's latest presentation at the FDA: the federal government is being populated by a combination of true renegades and middle ground scramblers who are dressed like renegades. A good toolkit for understanding how to make sense of the claims being made is necessary, and we all should be rooting for the renegades to win.*****Our sponsors:CrowdHealth: Pay for healthcare with crowdfunding instead of insurance. It's way better. Use code DarkHorse at JoinCrowdHealth.com to get 1st 3 months for $99/month.ARMRA Colostrum is an ancient bioactive whole food that can strengthen your immune system. Go to http://www.tryarmra.com/DARKHORSE to get 15% off your first order.Helix: Excellent, sleep-enhancing, American-made mattresses. Go to www.HelixSleep.com/DarkHorse for 27% Off - an offer exclusive for listeners of DarkHorse!*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:Trump's EO: https://www.whitehouse.gov/presidential-actions/2025/02/keeping-men-out-of-womens-sports/Paula Scanlan speaks about men in women's sports:https://x.com/xx_xyathletics/status/1940381615131332719U.K. Supreme Court: https://www.supremecourt.uk/cases/uksc-2024-0042The Lancet – sex isn't binary! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00834-7/fulltextU.S. Supreme Court – Mahmoud vs Taylor: https://www.supremecourt.gov/opinions/24pdf/24-297_4f14.pdfWilliam Thomas in the record books: https://www.outkick.com/sports/lia-thomas-upenn-womens-swimming-record-books-updated-acknowledges-transgender-swimmer-noteRFK Jr on Tucker: https://www.youtube.com/watch?v=w_fzlwxJZAAACIP committee with Robert Malone and Retsef Levi: https://x.com/janjekielek/status/1939482343313453423Prasad on myocarditis: https://x.com/US_FDA/status/1940111214497210425Prasad makes full professor: https://x.com/bretweinstein/status/1554849287300792320Earlier clips of ZDogg and Prasad and Makary: https://x.com/alexandrosm/status/1574530850565558272Support the show

In this episode, we continue our conversation with Bhanu Prasad, an Impact Innovation Coach at Digital Impact Square (DISQ), a social innovation center based in Nashik, Maharashtra. DISQ uses cutting-edge digital technologies to address key societal challenges across sectors like Health, Education, Water, and Environment, and has been instrumental in guiding young entrepreneurs towards creating meaningful solutions for India's growing needs. Bhanu delves into the transition of young entrepreneurs into mature founders, sharing insights on how DISQ's mentorship programs and innovation platforms are driving this transformation. He also discusses one of his favorite startup success stories, highlighting how impactful solutions are emerging from DISQ. In this episode, Bhanu sheds light on his experience coaching healthcare startups, which are solving critical health issues in India, and offers a look at the exciting ed-tech startups being nurtured at DISQ. As the episode unfolds, Bhanu also shares his vision for the future of DISQ, outlining how the center plans to continue scaling innovations to address pressing social challenges in India.✨ ABOUT ME ✨ Hello, my name is Vidyangi (Vida) Patil. I am a mindset coach, author, and speaker. Five years ago when I started understanding success hacks for individuals, startups, and larger organizations little did I know I would end up working with mentors hail from Silicon Valley at Stanford University, MIT Media Lab, Singularity University, and incubators and accelerators. All the way from guiding AI/ML startup founders in winning pitch competitions, and bagging investor appointments to helping youth entrepreneurs and women land their dream job or promotion, I plan to spill the beans of wisdom to launch you higher wherever you are in your life. I have successfully coached communities in social impact initiatives during COVID. Every week you will see new videos from me on career, personal growth, and technology trends to onboard your rocket ship to success!

In this episode of The Brand Called You, host Ashutosh Garg welcomes Prof T. Prasad, popularly known as "Mandi Sir" of IIM Mumbai. Prof Prasad shares his remarkable journey from being a daily wage countryside tailor to becoming a distinguished academic, founder of innovative education models, and mentor to several successful startups.Below, we break down the conversation into key questions with timestamp-based detail to guide you through this insightful episode.

In this episode, we are joined by Bhanu Prasad, an Impact Innovation Coach at Digital Impact Square (DISQ), an open social innovation center located in Nashik, Maharashtra. DISQ encourages the use of digital technologies to address significant social challenges in sectors such as Health, Hygiene, Housing, Transportation, Food, Agriculture, Energy, Water, Environment, Financial and Personal Security, Citizen Empowerment, Transparency, Education, and Skills Development across India. Founded on the collaborative principles inspired by the MIT Media Lab's Camera Culture research group, DISQ represents a unique platform where local communities, domain experts, the government, and industry partners converge to address these challenges. Through initiatives like the Kumbhathon, DISQ played a pivotal role in improving the experience at the Simhastha Kumbh Mela, one of the largest gatherings of human beings in the world. This effort not only enhanced visitor experiences but also demonstrated how technology-driven solutions can solve large-scale problems in real-time. Join us as Bhanu Prasad shares insights into DISQ's mission, the impact of digital innovations on social issues, and the incredible journey of leveraging technology for public good.✨ ABOUT ME ✨ Hello, my name is Vidyangi (Vida) Patil. I am a mindset coach, author, and speaker. Five years ago when I started understanding success hacks for individuals, startups, and larger organizations little did I know I would end up working with mentors hail from Silicon Valley at Stanford University, MIT Media Lab, Singularity University, and incubators and accelerators. All the way from guiding AI/ML startup founders in winning pitch competitions, and bagging investor appointments to helping youth entrepreneurs and women land their dream job or promotion, I plan to spill the beans of wisdom to launch you higher wherever you are in your life. I have successfully coached communities in social impact initiatives during COVID. Every week you will see new videos from me on career, personal growth, and technology trends to onboard your rocket ship to success!

In this powerful and deeply unsettling episode, Jonathan and Wendy take listeners on a guided tour of the growing dysfunction at America's top public health agencies. They expose the political entrenchment of ideologues like Vina Prasad and Marty Makary, the purging of veteran FDA scientists like Nicole Verdun, and the accelerating efforts to rubber-stamp drug approvals without oversight. Along the way, they dissect the roles of Jay Bhattacharya, Monica Gandhi, and others who—whether through naïveté or complicity—helped usher in a new era where science is optional and public health is performative. With deeply personal reflections, biting critique, and raw concern, they highlight a chilling truth: the institutions once trusted to safeguard health are now tools of political theater, and those who warned us early are watching their worst fears materialize. Connect with us further on https://sciencebasedmedicine.org/author/jonathanhoward/  The Fine Print The content presented in the "We Want Them Infected" Podcast and associated book is intended for informational and educational purposes only.    The views and opinions expressed by the speakers, hosts, and guests on the podcast do not necessarily reflect the views of the creators, producers, or distributors. The information provided in this podcast should not be considered as a substitute for professional medical, scientific, or legal advice. Listeners and readers are encouraged to consult with relevant experts and authorities for specific guidance and information.   The creators of the podcast and book have made reasonable efforts to ensure that the information provided is accurate and up to date. However, as the field of medical science and the understanding of the COVID-19 pandemic continue to evolve, there may be new developments and insights that are not covered in this content.   The creators are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. They disclaim any liability for any loss, injury, or damage incurred by individuals who rely on the content.   Listeners and readers are urged to use their judgment and conduct their own research when interpreting the information presented in the "We Want Them Infected" podcast and book. It is essential to stay informed about the latest updates, guidelines, and recommendations related to COVID-19 and vaccination from reputable sources, such as government health agencies and medical professionals. By accessing and using the content, you acknowledge and accept the terms of this disclaimer.   Please consult with appropriate experts and authorities for specific guidance on matters related to health, science, and the COVID-19 pandemic.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Nicole Verdun has exited the FDA as CBER director, allowing Vinay Prasad to consolidate power within the agency. Prasad is seen as a stabilizing and trustworthy figure within the rapidly changing FDA, especially since the departure of Peter Marks in late March. Novavax is adapting to regulatory uncertainty following the delayed approval of its next-generation COVID-19 vaccine. The company is relying on agility and a diverse pipeline to navigate changing regulations. Additionally, the FDA has frozen trials shipping cells to countries like China due to new export control policies. Exemptions have allowed companies to ship biological materials overseas, but this practice is now being restricted. Zealand's GLP-1/GLP-2 drug has shown promising results in weight loss trials, with analysts believing there is potential for further improvement. Intellia Therapeutics aims to transform the lives of people with severe diseases through genome editing treatments. Overall, the biotech industry is facing various challenges and changes, requiring companies to stay adaptable and innovative.

** Pre-order my new book: https://geni.us/AtlasOfUFOs ** I am joined by tech entrepreneur, physicist & experiencer, Deep Prasad to discuss: What Deep thinks is actually going on with UFOs The Continuous Spectrum of Interdimensional Beings The Rise of Private Space Companies The Role of NHI in Disclosure UFOs & Open Source Data Advancements in Anti-Gravity Research The Implications of AI and Model Collapse The Future Impact of AI on Society Listener Questions on AI Quantum Computing and Higher Dimensions Conclusion and Future Projects Check out Deeps work: https://x.com/Deepneuron https://www.sf-uap.com/ https://www.starvasa.space/our-origins Get in touch with the show: https://www.thatufopodcast.com/contact Twitter: @UFOUAPAM Facebook, YouTube & Instagram: "That UFO Podcast" YouTube: ⁠⁠YouTube.com/c/ThatUFOPodcast⁠⁠ Email: ⁠⁠UFOUAPAM@gmail.com All podcast links & associated links: ⁠⁠Linktr.ee/ufouapam⁠ https://www.thatufopodcast.com/ Don't forget to subscribe, like and leave a review of the show Enjoy folks, Andy

** Pre-order my new book: https://geni.us/AtlasOfUFOs ** I am joined by tech entrepreneur, physicist & experiencer, Deep Prasad to discuss: 00:00 Intro / Book promotion https://geni.us/AtlasOfUFOs 01:14 His Background and Achievements 03:17 Involvement in the UFO Community 04:18 AI and Material Science Innovations 10:37 The World's First UFO Hackathon 15:21 Hackathon Mission Tracks and Challenges 30:51 Future of UFO Detection and Public Involvement Check out Deeps work: https://x.com/Deepneuron https://www.sf-uap.com/ https://www.starvasa.space/our-origins Get in touch with the show: https://www.thatufopodcast.com/contact Twitter: @UFOUAPAM Facebook, YouTube & Instagram: "That UFO Podcast" YouTube: ⁠⁠YouTube.com/c/ThatUFOPodcast⁠⁠ Email: ⁠⁠UFOUAPAM@gmail.com All podcast links & associated links: ⁠⁠Linktr.ee/ufouapam⁠ https://www.thatufopodcast.com/ Don't forget to subscribe, like and leave a review of the show Enjoy folks, Andy

Janardan Prasad is the CEO of 101 GenAI - pioneering AI in healthcare. Previously he held leadership positions at Lore IO (acquired by Alteryx) and Knowlarity (acquired by Gupshup). He is an alum of IIT-Kanpur.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss why seemingly routine comments from Vinay Prasad, director of the US Food and Drug Administration's Center for Biologics Evaluation and Research, that he would stay away from daily review decisions were notable (:26), as well as the impact of proposed FDA budget cuts by the White House and the House of Representatives (17:16). More On These Topics From The Pink Sheet Prasad Says Involvement In US FDA Product Approvals Will Mirror Prior CBER Directors: https://insights.citeline.com/pink-sheet/rare-diseases/prasad-says-involvement-in-us-fda-product-approvals-will-mirror-prior-cber-directors-KF4LJWX5U5DLBMSM6D4YFL7ZOA/ To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says: https://insights.citeline.com/pink-sheet/advanced-technologies/cell-and-gene-therapies/to-compete-with-china-us-fda-must-deregulate-early-gene-therapy-studies-car-t-inventor-says-VDVXZGZIJZFHHNGGQXYILBI7RM/ FDA's FY 2026 Budget Request Lacks New Policy Proposals: https://insights.citeline.com/pink-sheet/legislation/fdas-fy-2026-budget-request-lacks-new-policy-proposals-WV3LE2AYBRAC7LIYJEU4WZDNGU/ User Fee-Funded Staff Would Drop In FY 2026 US FDA Budget: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/user-fee-funded-staff-would-drop-in-fy-2026-us-fda-budget-TQZMEB57V5GELNPMYGTY5BEGOY/ House Gives US FDA More Non-User Fee Funds Than Requested: https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/house-gives-us-fda-more-non-user-fee-funds-than-requested-PCQZCBHOB5ARPICMJJQ6VYIJ5M/

In 2016, Tulika was at the grocery store with her seven-year-old son, Vedant, who is non-verbal and autistic. When Vedant began to cry and pull her hair, a stranger helped Tulika in just the right way. Do you have your own story of an unsung hero? We'd love to hear it! Record a voice memo and email it to us at myunsunghero@hiddenbrain.org. Some guidance:--Focus on ONE moment that you will never forget. --Make sure you're in a quiet, non-echoey room.--Speak conversationally, like you're talking to a friend.--Let us know why this person continues to impact your life.--If your hero were standing in front of you today, what would you say? Address them directly.

Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets and programs could help realize that vision? On the latest BioCentury This Week podcast, BioCentury's editors discuss the signaling pathways that may exclusively target fat mass while preserving, or even increasing, lean mass — and which companies are playing in the space.The editors also assess what Vinay Prasad's past comments say about how he might lead FDA's Center for Biologics Evaluation and Research (CBER) — and examine how investors are evaluating the possibility that he might move the bar for regulatory approvals. The team then introduces the first in a new BioCentury series, with a look at a Literature Dive into ovarian cancer “atlases” — large-scale molecular profiling studies that point to predictive signatures and patient stratification strategies. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655898#biotech #biopharma #pharma #obesity #FDA #CBER #LifeScience #OvarianCancer00:01 - Sponsor Message: Jeito Capital03:22 - Obesity: Quality over Quantity15:47 - Prasad at FDA27:58 - Ovarian Cancer AtlasesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

TODAY ON THE ROBERT SCOTT BELL SHOW: Prasad In, Marks Out, NIH Shuts Beagle Lab, Placebo Trial Backlash, Hydroxychloroquine Study Retracted, Copaiva Officinalis, Karma Bias, Drug-Induced Nutritional Deficiencies, Florida Bans Fluoride, RFK Jr. Autism Critics, Food Beats Painkillers, and MORE! https://robertscottbell.com/prasad-in-marks-out-nih-shuts-beagle-lab-placebo-trial-backlash-hydroxychloroquine-study-retracted-copaiva-officinalis-karma-bias-drug-induced-nutritional-deficiencies-florida-bans-fluoride-r/ Please read this disclaimer carefully before you (“you”, “your”) use our [Your Website URL] website (“website”, “service”) operated by the [Your Business Name] (“operator”, “us”, “we”, “our”). Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing t